Astrazeneca Pharma India Ltd vs Gufic Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8396 as of 07 May 10:37 . The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2024 .The P/E Ratio of Gufic BioSciences Ltd is 33 as of March 2024 . The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Gufic BioSciences Ltd is ₹ 2839 crore as of March 2024 . The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Gufic BioSciences Ltd for the Dec '25 is ₹ 232.2 crore as compare to the Sep '25 revenue of ₹ 239.17 crore. This represent the decline of -2.91% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Gufic BioSciences Ltd for the Dec '25 is ₹ 33.77 crore as compare to the Sep '25 ebitda of ₹ 39.96 crore. This represent the decline of -15.49% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Gufic BioSciences Ltd changed from ₹ 20.86 crore to ₹ 12.42 crore over 7 quarters. This represents a CAGR of -25.64% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Gufic BioSciences Ltd changed from 2.19 % on March 2021 to 1.43 % on March 2025 . This represents a CAGR of -8.17% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Gufic BioSciences Ltd

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
The Company was incorporated in July, 1984.
The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Gufic BioSciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr while Market cap of Gufic BioSciences Ltd is 2,938 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd?

As of May 7, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8369.45. On the other hand, Gufic BioSciences Ltd stock price is INR ₹293.0.

How do dividend payouts of Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Gufic BioSciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.